{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:51:41Z","timestamp":1793685101038,"version":"4.5.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-Hodgkin lymphoma (NHL) constitutes a biologically and clinically heterogeneous group of lymphoid malignancies, with varying prognoses and treatment aims between indolent and aggressive subtypes. While survival outcomes remain key efficacy measures, they insufficiently capture the impact of disease and treatment on daily physical and psychosocial functioning, as well as quality of life (QoL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To characterize the use and reporting of patient-reported outcomes (PROs) in adult NHL randomized controlled trials (RCTs), including the trajectory of PRO dissemination throughout the trial reporting process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MEDLINE, CENTRAL, ClinicalTrials.gov, and WHO ICTRP were systematically searched from 1 January 2017 to 19 January 2023 for NHL RCTs irrespective of subtype, with databases being re-searched until 4 February 2025. Cross-sectional and longitudinal descriptive analyses were conducted to investigate PRO use and reporting practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>549 completed and ongoing RCTs met the eligibility criteria, of which 176 trials (32.1%) included a reference to PROs, and 27 (4.9%) used a PRO as a primary outcome. Overall, 95 PRO measures were identified across trials, with EORTC QLQ-C30, FACT-Lymphoma, and EQ-5D being referenced most frequently. Among trials with published results that pre-specified PROs, 25.0% entirely and 10.5% partly omitted PRO findings from their main full-texts, without addressing this shortcoming in subsequent publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PROs are underused and underreported in RCTs in NHL. Standardized PRO evaluation methodology and guidance for the selection of fit-for-purpose PRO measures are needed, along with clear positioning of PROs alongside survival outcomes in clinical trial design and interpretation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-026-00999-1","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:06:00Z","timestamp":1769616360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use and reporting of patient-reported outcomes in randomized controlled trials in non-Hodgkin lymphoma: a scoping review"],"prefix":"10.1186","volume":"10","author":[{"given":"Julia","family":"Schroer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Jan","family":"Br\u00f6ckelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Salek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Ionova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Laane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Natalie","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Csenar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"999_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBDO, Berti E et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36:1720\u20131748","journal-title":"Leukemia"},{"key":"999_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A cancer. J Clin 74:229\u2013263","journal-title":"J Clin"},{"key":"999_CR3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/ajh.26719","volume":"97","author":"MS Alabdaljabar","year":"2022","unstructured":"Alabdaljabar MS, Durani U, Thompson CA, Constine LS, Hashmi SK (2022) The forgotten survivor: A comprehensive review on Non-Hodgkin lymphoma survivorship. Am J Hematol 97:1627\u20131637","journal-title":"Am J Hematol"},{"key":"999_CR4","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/bjh.18139","volume":"197","author":"A Ekels","year":"2022","unstructured":"Ekels A, Van De Poll-Franse LV, Posthuma EFM, Kieffer J, Issa DE, Koster A et al (2022) Persistent symptoms of fatigue, neuropathy and role\u2010functioning impairment among indolent non\u2010Hodgkin lymphoma survivors: A longitudinal PROFILES registry study. Br J Haematol 197:590\u2013601","journal-title":"Br J Haematol"},{"key":"999_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","volume":"10","author":"CL Batlevi","year":"2020","unstructured":"Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z et al (2020) Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J 10:74","journal-title":"Blood Cancer J"},{"key":"999_CR6","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H Schulz","year":"2007","unstructured":"Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T et al (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. JNCI J Natl Cancer Inst 99:706\u2013714","journal-title":"JNCI J Natl Cancer Inst"},{"key":"999_CR7","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1016\/S2352-3026(25)00051-1","volume":"12","author":"PJ Br\u00f6ckelmann","year":"2025","unstructured":"Br\u00f6ckelmann PJ, Scheffer Cliff ER, Iacoboni G, Simon F, Horowitz MM, Keating A et al (2025) Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies. Lancet Haematol 12:e470\u2013e81","journal-title":"Lancet Haematol"},{"key":"999_CR8","doi-asserted-by":"crossref","unstructured":"Health, USDo et al (2006) Human Services FDACfDE, Research, Health USDo, Human Services FDACfBE, Research,. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health and Quality of Life Outcomes 4:79","DOI":"10.1186\/1477-7525-4-79"},{"key":"999_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/bjaed\/mkw060","volume":"17","author":"C Kingsley","year":"2017","unstructured":"Kingsley C, Patel S (2017) Patient-reported outcome measures and patient-reported experience measures. BJA Educ 17:137\u2013144","journal-title":"BJA Educ"},{"key":"999_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/17407745221077691","volume":"19","author":"C Snyder","year":"2022","unstructured":"Snyder C, Crossnohere N, King M, Reeve BB, Bottomley A, Calvert M et al (2022) The PROTEUS-Trials consortium: optimizing the use of patient-reported outcomes in clinical trials. Clin Trails 19:277\u2013284","journal-title":"Clin Trails"},{"key":"999_CR11","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1016\/S2352-3026(25)00036-5","volume":"12","author":"V Bhatnagar","year":"2025","unstructured":"Bhatnagar V, Dueck AC, Efficace F, Kluetz P, Minasian L, Velikova G et al (2025) Beyond maximum grade: using patient-generated data to inform tolerability of treatments for haematological malignancies. Lancet Haematol 12:e463\u2013e9","journal-title":"Lancet Haematol"},{"key":"999_CR12","doi-asserted-by":"publisher","first-page":"5764","DOI":"10.3390\/cancers15245764","volume":"15","author":"E Laane","year":"2023","unstructured":"Laane E, Salek S, Oliva EN, Bennink C, Clavreul S, Richardson PG et al (2023) Guidelines for the use and reporting of Patient-Reported outcomes in multiple myeloma clinical trials. Cancers 15:5764","journal-title":"Cancers"},{"key":"999_CR13","doi-asserted-by":"crossref","unstructured":"Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L et al (2020) Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synthesis 18","DOI":"10.11124\/JBIES-20-00167"},{"key":"999_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169:467\u2013473","journal-title":"Ann Intern Med"},{"key":"999_CR15","first-page":"84","volume":"105","author":"WM Bramer","year":"2017","unstructured":"Bramer WM, Milic J, Mast F (2017) Reviewing retrieved references for inclusion in systematic reviews using endnote. J Med Libr Association: JMLA 105:84\u201387","journal-title":"J Med Libr Association: JMLA"},{"key":"999_CR16","unstructured":"Lefebvre CGJ, Briscoe S, Featherstone R, Littlewood A, Metzendorf M-I, Noel-Storr A, Paynter R, Rader T, Thomas J, Wieland LS (2025) Chapter 4: searching for and selecting studies [last updated March 2025]. In: Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version, 651. Cochrane"},{"key":"999_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol 8:19\u201332","journal-title":"Int J Soc Res Methodol"},{"key":"999_CR18","unstructured":"Li T, Higgins J, Deeks J (2023) Chapter 5: collecting data. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V (eds) Cochrane handbook for systematic reviews of interventions version 64. Cochrane. (updated August 2023)"},{"key":"999_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.18697","volume":"201","author":"MR Wilson","year":"2023","unstructured":"Wilson MR, Barrett A, Cheah CY, Eyre TA (2023) How I manage mantle cell lymphoma: indolent versus aggressive disease. Br J Haematol 201:185\u2013198","journal-title":"Br J Haematol"},{"key":"999_CR20","unstructured":"ClinicalTrials.gov (2024) ClinicalTrials.gov Glossary Terms"},{"key":"999_CR21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jclinepi.2020.11.003","volume":"133","author":"J Thomas","year":"2021","unstructured":"Thomas J, McDonald S, Noel-Storr A, Shemilt I, Elliott J, Mavergames C, Marshall IJ (2021) Machine learning reduced workload with minimal risk of missing studies: development and evaluation of a randomized controlled trial classifier for Cochrane reviews. J Clin Epidemiol 133:140\u2013151","journal-title":"J Clin Epidemiol"},{"key":"999_CR22","doi-asserted-by":"publisher","DOI":"10.3768\/rtipress.2015.bk.0014.1509","volume-title":"Types of Patient-Reported outcomes","author":"D Cella","year":"2015","unstructured":"Cella D, Hahn EA, Jensen SE, Butt Z, Nowinski CJ, Rothrock N, Lohr KN (2015) Types of Patient-Reported outcomes. RTI, Patient-Reported Outcomes in Performance Measurement"},{"key":"999_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0959-8049(01)00448-8","volume":"38","author":"P Fayers","year":"2002","unstructured":"Fayers P, Bottomley A (2002) Quality of life research within the EORTC\u2014the EORTC QLQ-C30. Eur J Cancer 38:125\u2013133","journal-title":"Eur J Cancer"},{"key":"999_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-1-79","volume":"1","author":"K Webster","year":"2003","unstructured":"Webster K, Cella D, Yost K (2003) The F unctional A ssessment of C Hronic I Llness T herapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1:79","journal-title":"Health Qual Life Outcomes"},{"key":"999_CR25","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/bjh.19918","volume":"206","author":"MAV Marzolini","year":"2025","unstructured":"Marzolini MAV, Qian W, Clifton-Hadley L, Patrick P, Warden J, Stevens L et al (2025) Quality of life in advanced\u2010stage, asymptomatic, non\u2010bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful\u2010waiting. Br J Haematol 206:876\u2013886","journal-title":"Br J Haematol"},{"key":"999_CR26","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1093\/annonc\/mdw685","volume":"28","author":"M Rummel","year":"2017","unstructured":"Rummel M, Kim TM, Aversa F, Brugger W, Capochiani E, Plenteda C et al (2017) Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20\u2009+\u2009diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol 28:836\u2013842","journal-title":"Ann Oncol"},{"key":"999_CR27","doi-asserted-by":"publisher","first-page":"e2414425","DOI":"10.1001\/jamanetworkopen.2024.14425","volume":"7","author":"K Patel","year":"2024","unstructured":"Patel K, Ivanov A, Jocelyn T, Hantel A, Garcia JS, Abel GA (2024) Patient-Reported outcomes in phase 3 clinical trials for blood cancers: A systematic review. JAMA Netw Open 7:e2414425","journal-title":"JAMA Netw Open"},{"key":"999_CR28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.clml.2024.07.018","volume":"25","author":"A Major","year":"2025","unstructured":"Major A, Dueck AC, Thanarajasingam G (2025) SOHO state of the Art updates and next questions | measuring Patient-Reported outcomes (PROs) and treatment tolerability in patients with hematologic malignancies. Clin Lymphoma Myeloma Leuk 25:142\u2013155","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"999_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1053\/j.seminhematol.2024.10.010","volume":"61","author":"T Mendoza","year":"2024","unstructured":"Mendoza T, King AL, Vera E, Mina A, McGraw K, Pavletic S, Armstrong TS (2024) Patient-reported outcomes in early phase trials for patients with myelodysplastic syndromes. Semin Hematol 61:457\u2013464","journal-title":"Semin Hematol"},{"key":"999_CR30","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1182\/blood-2019-128741","volume":"134","author":"AJ Messina","year":"2019","unstructured":"Messina AJ, O\u2019Brien QE, Andrianov V, Moss KR, Vidal L, Vidal-Fisher L (2019) Under reporting of patient reported outcomes (PROs) in myeloproliferative neoplasm (MPN) clinical trials. Blood 134:4754","journal-title":"Blood"},{"key":"999_CR31","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1182\/blood-2018-99-114464","volume":"132","author":"L Vidal-Fisher","year":"2018","unstructured":"Vidal-Fisher L, Curtis KK, Vidal L, Moss KR (2018) Under-Reporting of patient reported outcome (PRO) in clinical trials. Blood 132:3583","journal-title":"Blood"},{"key":"999_CR32","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1007\/s11136-022-03119-w","volume":"31","author":"R Mercieca-Bebber","year":"2022","unstructured":"Mercieca-Bebber R, Aiyegbusi OL, King MT, Brundage M, Snyder C, Calvert M (2022) Knowledge translation concerns for the CONSORT-PRO extension reporting guidance: a review of reviews. Qual Life Res 31:2939\u20132957","journal-title":"Qual Life Res"},{"key":"999_CR33","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1016\/S2352-3026(25)00032-8","volume":"12","author":"CJ Milrod","year":"2025","unstructured":"Milrod CJ, Rubin L, Martinez B, Ollila TA, Olszewski AJ, Pelcovits A (2025) Quality-of-life endpoints collection, reporting, and framing in randomised trials of indolent lymphomas: a systematic review. Lancet Haematol 12:e312\u2013e7","journal-title":"Lancet Haematol"},{"key":"999_CR34","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jama.2013.879","volume":"309","author":"M Calvert","year":"2013","unstructured":"Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD (2013) Consort pro group FT. Reporting of Patient-Reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309:814","journal-title":"JAMA"},{"key":"999_CR35","doi-asserted-by":"publisher","first-page":"S353","DOI":"10.1016\/j.jval.2023.03.2397","volume":"26","author":"AF Mohamed","year":"2023","unstructured":"Mohamed AF, Kandikatla R, Thirugnanam A, Patel NM, Patel U, Yunusa I et al (2023) PCR218 evaluating the adherence of reporting patient reported outcomes to the consort PRO extension, CONSORT-Outcomes extension and ISOQOL standards among aggressive large B cell lymphoma patients: systematic literature review of RCTs. Value Health 26:S353","journal-title":"Value Health"},{"key":"999_CR36","doi-asserted-by":"publisher","first-page":"e892","DOI":"10.1016\/S2352-3026(20)30292-1","volume":"7","author":"R Chakraborty","year":"2020","unstructured":"Chakraborty R, Cannella L, Cottone F, Efficace F (2020) Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review. Lancet Haematol 7:e892\u2013e901","journal-title":"Lancet Haematol"},{"key":"999_CR37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejca.2021.04.023","volume":"152","author":"D Riedl","year":"2021","unstructured":"Riedl D, Rothmund M, Darlington A-S, Sodergren S, Crazzolara R, De Rojas T (2021) Rare use of patient-reported outcomes in childhood cancer clinical trials \u2013 a systematic review of clinical trial registries. Eur J Cancer 152:90\u201399","journal-title":"Eur J Cancer"},{"key":"999_CR38","doi-asserted-by":"crossref","unstructured":"Murugappan MN, King-Kallimanis BL, Reaman GH, Bhatnagar V, Horodniceanu EG, Bouchkouj N, Kluetz PG (2022) Patient-Reported outcomes in pediatric cancer registration trials: A US food and drug administration perspective. JNCI: J Natl Cancer Inst 114:12\u201319","DOI":"10.1093\/jnci\/djab087"},{"key":"999_CR39","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.1182\/blood-2018-99-117180","volume":"132","author":"P Goswami","year":"2018","unstructured":"Goswami P, Oliva EN, Ionova T, Salek S (2018) Translating the science of patient reported outcomes into practice: meaningfulness of HM-PRO scores in patients with hematological malignancies. Blood 132:4860","journal-title":"Blood"},{"key":"999_CR40","doi-asserted-by":"publisher","first-page":"114210","DOI":"10.1016\/j.ejca.2024.114210","volume":"208","author":"A Anota","year":"2024","unstructured":"Anota A, Basset M, Charton E, Bommier C, Efficace F, Dupuis J et al (2024) Health-related quality of life profile of newly diagnosed patients with hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort. Eur J Cancer 208:114210","journal-title":"Eur J Cancer"},{"key":"999_CR41","unstructured":"International Society for Quality of Life Research (prepared by Aaronson N ET, Greenhalgh J, Halyard M, Hess R, Miller D, Reeve B, Santana M, Snyder C (2015) User\u2019s guide to implementing patient-reported outcomes assessment in clinical practice version 2"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-026-00999-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-00999-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-00999-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:16:26Z","timestamp":1781630186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-026-00999-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["999"],"URL":"https:\/\/doi.org\/10.1186\/s41687-026-00999-1","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ENO: received honoraria for providing and participating in speaker\u2019s panels for AbbVie, Alexion, Amgen, Janssen, Daiichi, and Novartis; is copyright holder of the QOL-E instrument and the HM-PRO.PJB: received research funding from BeOne (institution), BMS (institution), MSD (institution), and Takeda (institution); advisor or consultant for Hexal, MSD, Need Inc., Stemline, and Takeda; received honoraria from AstraZeneca, BeOne, BMS\/Celgene, Eli Lilly, MSD, Need Inc., Stemline, and Takeda; has stock options in Need Inc.; received the Excellence Stipend by the Else Kr\u00f6ner-Fresenius Foundation (EKFS).SS: received honoraria for providing consultancy to NovoNordisk and AbbVie; is copyright holder of several instruments, including FROM-16, MLCDP, TQoL, HidroQoL, PDF, RQLP, and the HM-PRO.TI: is copyright holder of the HM-PRO.EL, IM, JS, MC, NS: none known.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}